Veterans advocates say they are frustrated at the lack of transparency around the Department of Veterans Affairs' use of the unproven drug hydroxychloroquine as a treatment for the coronavirus. After the release of a preliminary study of veterans hospitalized with COVID-19 last week that showed that hydroxychloroquine — an anti-malaria drug touted by President Donald Trump — had no benefit and caused a greater rate of deaths, the groups want answers and are worried that they may have been misled by the agency on its recent purchase of the drug. Jeremy Butler, CEO of Iraq and Afghanistan Veterans of America,...